Skip to content

Bristol Myers Squibb Co

NYSE: BMY · USD

Bristol Myers Squibb Co financials

6 charts

Revenue

USD millions

$12,973M
Bristol Myers Squibb Co Revenue. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodRevenue
FY 2009 Q2$5,384M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$5,487M; +1.9% vs FY 2009 Q2
FY 2009 Q4$5,033M; −8.3% vs FY 2009 Q3
FY 2010 Q1$4,807M; −4.5% vs FY 2009 Q4
FY 2010 Q2$4,768M; −0.8% vs FY 2010 Q1
FY 2010 Q3$4,798M; +0.6% vs FY 2010 Q2
FY 2010 Q4$5,111M; +6.5% vs FY 2010 Q3
FY 2011 Q1$5,011M; −2.0% vs FY 2010 Q4
FY 2011 Q2$5,434M; +8.4% vs FY 2011 Q1
FY 2011 Q3$5,345M; −1.6% vs FY 2011 Q2
FY 2011 Q4$5,454M; +2.0% vs FY 2011 Q3
FY 2012 Q1$5,251M; −3.7% vs FY 2011 Q4
FY 2012 Q2$4,443M; −15.4% vs FY 2012 Q1
FY 2012 Q3$3,736M; −15.9% vs FY 2012 Q2
FY 2012 Q4$4,191M; +12.2% vs FY 2012 Q3
FY 2013 Q1$3,831M; −8.6% vs FY 2012 Q4
FY 2013 Q2$4,048M; +5.7% vs FY 2013 Q1
FY 2013 Q3$4,065M; +0.4% vs FY 2013 Q2
FY 2013 Q4$4,441M; +9.2% vs FY 2013 Q3
FY 2014 Q1$3,811M; −14.2% vs FY 2013 Q4
FY 2014 Q2$3,889M; +2.0% vs FY 2014 Q1
FY 2014 Q3$3,921M; +0.8% vs FY 2014 Q2
FY 2014 Q4$4,258M; +8.6% vs FY 2014 Q3
FY 2015 Q1$4,041M; −5.1% vs FY 2014 Q4
FY 2015 Q2$4,163M; +3.0% vs FY 2015 Q1
FY 2015 Q3$4,069M; −2.3% vs FY 2015 Q2
FY 2015 Q4$4,287M; +5.4% vs FY 2015 Q3
FY 2016 Q1$4,391M; +2.4% vs FY 2015 Q4
FY 2016 Q2$4,871M; +10.9% vs FY 2016 Q1
FY 2016 Q3$4,922M; +1.0% vs FY 2016 Q2
FY 2016 Q4$5,243M; +6.5% vs FY 2016 Q3
FY 2017 Q1$4,929M; −6.0% vs FY 2016 Q4
FY 2017 Q2$5,144M; +4.4% vs FY 2017 Q1
FY 2017 Q3$5,254M; +2.1% vs FY 2017 Q2
FY 2017 Q4$5,449M; +3.7% vs FY 2017 Q3
FY 2018 Q1$5,193M; −4.7% vs FY 2017 Q4
FY 2018 Q2$5,704M; +9.8% vs FY 2018 Q1
FY 2018 Q3$5,691M; −0.2% vs FY 2018 Q2
FY 2018 Q4$5,973M; +5.0% vs FY 2018 Q3
FY 2019 Q1$5,920M; −0.9% vs FY 2018 Q4
FY 2019 Q2$6,273M; +6.0% vs FY 2019 Q1
FY 2019 Q3$6,007M; −4.2% vs FY 2019 Q2
FY 2019 Q4$7,945M; +32.3% vs FY 2019 Q3
FY 2020 Q1$10,781M; +35.7% vs FY 2019 Q4
FY 2020 Q2$10,129M; −6.0% vs FY 2020 Q1
FY 2020 Q3$10,540M; +4.1% vs FY 2020 Q2
FY 2020 Q4$11,068M; +5.0% vs FY 2020 Q3
FY 2021 Q1$11,073M; 0.0% vs FY 2020 Q4
FY 2021 Q2$11,703M; +5.7% vs FY 2021 Q1
FY 2021 Q3$11,624M; −0.7% vs FY 2021 Q2
FY 2021 Q4$11,985M; +3.1% vs FY 2021 Q3
FY 2022 Q1$11,648M; −2.8% vs FY 2021 Q4
FY 2022 Q2$11,887M; +2.1% vs FY 2022 Q1
FY 2022 Q3$11,218M; −5.6% vs FY 2022 Q2
FY 2022 Q4$11,406M; +1.7% vs FY 2022 Q3
FY 2023 Q1$11,337M; −0.6% vs FY 2022 Q4
FY 2023 Q2$11,226M; −1.0% vs FY 2023 Q1
FY 2023 Q3$10,966M; −2.3% vs FY 2023 Q2
FY 2023 Q4$11,477M; +4.7% vs FY 2023 Q3
FY 2024 Q1$11,865M; +3.4% vs FY 2023 Q4
FY 2024 Q2$12,201M; +2.8% vs FY 2024 Q1
FY 2024 Q3$11,892M; −2.5% vs FY 2024 Q2
FY 2024 Q4$12,342M; +3.8% vs FY 2024 Q3
FY 2025 Q1$11,201M; −9.2% vs FY 2024 Q4
FY 2025 Q2$12,269M; +9.5% vs FY 2025 Q1
FY 2025 Q3$12,222M; −0.4% vs FY 2025 Q2
FY 2025 Q4$12,502M; +2.3% vs FY 2025 Q3
FY 2026 Q1$11,489M; −8.1% vs FY 2025 Q4
FY 2026 Q2$12,973M; +12.9% vs FY 2026 Q1
Jun 30, 2009 through Sep 25, 2026

Free cash flow

USD millions

$3,088M
Bristol Myers Squibb Co Free cash flow. Quarterly values and changes versus the preceding comparable period. Missing values are unavailable.
PeriodFree cash flow
FY 2009 Q2$632M; Change unavailable vs FY 2009 Q1
FY 2009 Q3$1,304M; +106.3% vs FY 2009 Q2
FY 2009 Q4$1,148M; −12.0% vs FY 2009 Q3
FY 2010 Q1$335M; −70.8% vs FY 2009 Q4
FY 2010 Q2$968M; +189.0% vs FY 2010 Q1
FY 2010 Q3$1,294M; +33.7% vs FY 2010 Q2
FY 2010 Q4$1,470M; +13.6% vs FY 2010 Q3
FY 2011 Q1$406M; −72.4% vs FY 2010 Q4
FY 2011 Q2$1,019M; +151.0% vs FY 2011 Q1
FY 2011 Q3$1,614M; +58.4% vs FY 2011 Q2
FY 2011 Q4$1,434M; −11.2% vs FY 2011 Q3
FY 2012 Q1$264M; −81.6% vs FY 2011 Q4
FY 2012 Q2$1,021M; +286.7% vs FY 2012 Q1
FY 2012 Q3$4,447M; +335.6% vs FY 2012 Q2
FY 2012 Q4$661M; −85.1% vs FY 2012 Q3
FY 2013 Q1$-543M; −182.1% vs FY 2012 Q4
FY 2013 Q2$1,412M; +360.0% vs FY 2013 Q1
FY 2013 Q3$929M; −34.2% vs FY 2013 Q2
FY 2013 Q4$1,210M; +30.2% vs FY 2013 Q3
FY 2014 Q1$499M; −58.8% vs FY 2013 Q4
FY 2014 Q2$946M; +89.6% vs FY 2014 Q1
FY 2014 Q3$796M; −15.9% vs FY 2014 Q2
FY 2014 Q4$381M; −52.1% vs FY 2014 Q3
FY 2015 Q1$490M; +28.6% vs FY 2014 Q4
FY 2015 Q2$-94M; −119.2% vs FY 2015 Q1
FY 2015 Q3$290M; +408.5% vs FY 2015 Q2
FY 2015 Q4$326M; +12.4% vs FY 2015 Q3
FY 2016 Q1$-628M; −292.6% vs FY 2015 Q4
FY 2016 Q2$150M; +123.9% vs FY 2016 Q1
FY 2016 Q3$1,056M; +604.0% vs FY 2016 Q2
FY 2016 Q4$1,057M; +0.1% vs FY 2016 Q3
FY 2017 Q1$570M; −46.1% vs FY 2016 Q4
FY 2017 Q2$1,336M; +134.4% vs FY 2017 Q1
FY 2017 Q3$1,451M; +8.6% vs FY 2017 Q2
FY 2017 Q4$863M; −40.5% vs FY 2017 Q3
FY 2018 Q1$936M; +8.5% vs FY 2017 Q4
FY 2018 Q2$859M; −8.2% vs FY 2018 Q1
FY 2018 Q3$1,055M; +22.8% vs FY 2018 Q2
FY 2018 Q4$2,139M; +102.7% vs FY 2018 Q3
FY 2019 Q1$1,186M; −44.6% vs FY 2018 Q4
FY 2019 Q2$1,892M; +59.5% vs FY 2019 Q1
FY 2019 Q3$2,366M; +25.1% vs FY 2019 Q2
FY 2019 Q4$1,787M; −24.5% vs FY 2019 Q3
FY 2020 Q1$3,708M; +107.5% vs FY 2019 Q4
FY 2020 Q2$4,138M; +11.6% vs FY 2020 Q1
FY 2020 Q3$2,066M; −50.1% vs FY 2020 Q2
FY 2020 Q4$3,387M; +63.9% vs FY 2020 Q3
FY 2021 Q1$3,651M; +7.8% vs FY 2020 Q4
FY 2021 Q2$2,850M; −21.9% vs FY 2021 Q1
FY 2021 Q3$4,996M; +75.3% vs FY 2021 Q2
FY 2021 Q4$3,737M; −25.2% vs FY 2021 Q3
FY 2022 Q1$3,559M; −4.8% vs FY 2021 Q4
FY 2022 Q2$1,989M; −44.1% vs FY 2022 Q1
FY 2022 Q3$3,440M; +73.0% vs FY 2022 Q2
FY 2022 Q4$2,960M; −14.0% vs FY 2022 Q3
FY 2023 Q1$2,692M; −9.1% vs FY 2022 Q4
FY 2023 Q2$1,628M; −39.5% vs FY 2023 Q1
FY 2023 Q3$4,409M; +170.8% vs FY 2023 Q2
FY 2023 Q4$3,922M; −11.0% vs FY 2023 Q3
FY 2024 Q1$2,550M; −35.0% vs FY 2023 Q4
FY 2024 Q2$2,064M; −19.1% vs FY 2024 Q1
FY 2024 Q3$5,267M; +155.2% vs FY 2024 Q2
FY 2024 Q4$4,061M; −22.9% vs FY 2024 Q3
FY 2025 Q1$1,694M; −58.3% vs FY 2024 Q4
FY 2025 Q2$3,556M; +109.9% vs FY 2025 Q1
FY 2025 Q3$5,991M; +68.5% vs FY 2025 Q2
FY 2025 Q4$1,604M; −73.2% vs FY 2025 Q3
FY 2026 Q1$757M; −52.8% vs FY 2025 Q4
FY 2026 Q2$3,088M; +307.9% vs FY 2026 Q1

Net margin

%

25.57%
Bristol Myers Squibb Co Net margin. Reported fiscal history.
Fiscal period%
FY 2009 Q218.26%
FY 2009 Q317.61%
FY 2009 Q4159.45%
FY 2010 Q115.46%
FY 2010 Q219.44%
FY 2010 Q319.78%
FY 2010 Q49.45%
FY 2011 Q119.68%
FY 2011 Q216.6%
FY 2011 Q318.13%
FY 2011 Q415.62%
FY 2012 Q120.97%
FY 2012 Q214.52%
FY 2012 Q3-19.03%
FY 2012 Q422.07%
FY 2013 Q115.9%
FY 2013 Q213.24%
FY 2013 Q317.02%
FY 2013 Q416.35%
FY 2014 Q124.59%
FY 2014 Q28.56%
FY 2014 Q318.39%
FY 2014 Q40.31%
FY 2015 Q129.35%
FY 2015 Q2-3.12%
FY 2015 Q317.35%
FY 2015 Q4-4.6%
FY 2016 Q127.21%
FY 2016 Q223.94%
FY 2016 Q324.42%
FY 2016 Q417.05%
FY 2017 Q131.93%
FY 2017 Q217.81%
FY 2017 Q316.08%
FY 2017 Q4-42.72%
FY 2018 Q128.62%
FY 2018 Q26.54%
FY 2018 Q333.4%
FY 2018 Q419.42%
FY 2019 Q128.89%
FY 2019 Q222.83%
FY 2019 Q322.52%
FY 2019 Q4-13.29%
FY 2020 Q1-7.19%
FY 2020 Q2-0.84%
FY 2020 Q317.76%
FY 2020 Q4-90.59%
FY 2021 Q118.25%
FY 2021 Q29.01%
FY 2021 Q313.3%
FY 2021 Q419.79%
FY 2022 Q110.97%
FY 2022 Q211.95%
FY 2022 Q314.32%
FY 2022 Q417.73%
FY 2023 Q119.95%
FY 2023 Q218.47%
FY 2023 Q317.58%
FY 2023 Q415.35%
FY 2024 Q1-100.39%
FY 2024 Q213.77%
FY 2024 Q310.18%
FY 2024 Q40.58%
FY 2025 Q121.93%
FY 2025 Q210.68%
FY 2025 Q318.01%
FY 2025 Q48.69%
FY 2026 Q123.3%
FY 2026 Q225.57%

P/E

× · TTM · Daily

13.87×
Bristol Myers Squibb Co P/E. Monthly closing observations; inspect daily values with the chart arrow keys.
Close date× · TTM · DailyFinancials through
2012-02-295.22×2010-09-30
2012-03-305.47×2010-09-30
2012-04-305.41×2010-09-30
2012-05-315.41×2010-09-30
2012-06-295.83×2010-09-30
2012-07-315.77×2010-09-30
2012-08-315.35×2010-09-30
2012-09-285.47×2010-09-30
2012-10-315.39×2010-09-30
2012-11-305.29×2010-09-30
2012-12-315.28×2010-09-30
2013-01-315.86×2010-09-30
2013-02-2819.02×2011-09-30
2013-03-2821.19×2011-09-30
2013-04-3020.43×2011-09-30
2013-05-3123.67×2011-09-30
2013-06-2822.99×2011-09-30
2013-07-3122.24×2011-09-30
2013-08-3021.45×2011-09-30
2013-09-3023.81×2011-09-30
2013-10-3127.02×2011-09-30
2013-11-2926.43×2011-09-30
2013-12-3127.34×2011-09-30
2014-01-3125.7×2011-09-30
2014-02-2845.6×2012-12-31
2014-03-3144.05×2012-12-31
2014-04-3042.48×2012-12-31
2014-05-3042.18×2012-12-31
2014-06-3041.14×2012-12-31
2014-07-3142.92×2012-12-31
2014-08-2942.95×2012-12-31
2014-09-3043.4×2012-12-31
2014-10-3149.34×2012-12-31
2014-11-2850.07×2012-12-31
2014-12-3150.06×2012-12-31
2015-01-3051.11×2012-12-31
2015-02-2750.95×2014-12-31
2015-03-3153.94×2014-12-31
2015-04-3047.41×2015-03-31
2015-05-2948.06×2015-03-31
2015-06-3049.5×2015-03-31
2015-07-3161.13×2015-06-30
2015-08-3155.38×2015-06-30
2015-09-3055.13×2015-06-30
2015-10-3062.35×2015-09-30
2015-11-3063.35×2015-09-30
2015-12-3165.03×2015-09-30
2016-01-2958.76×2015-09-30
2016-02-2966.68×2015-12-31
2016-03-3168.78×2015-12-31
2016-04-2977.04×2016-03-31
2016-05-3176.53×2016-03-31
2016-06-3078.5×2016-03-31
2016-07-2943.77×2016-06-30
2016-08-3133.57×2016-06-30
2016-09-3031.54×2016-06-30
2016-10-3125.39×2016-09-30
2016-11-3028.15×2016-09-30
2016-12-3029.15×2016-09-30
2017-01-3124.52×2016-09-30
2017-02-2821.41×2016-12-31
2017-03-3120.53×2016-12-31
2017-04-2821.16×2016-12-31
2017-05-3120.37×2016-12-31
2017-06-3021.04×2016-12-31
2017-07-3121.49×2016-12-31
2017-08-3122.84×2016-12-31
2017-09-2924.07×2016-12-31
2017-10-3123.28×2016-12-31
2017-11-3023.86×2016-12-31
2017-12-2923.14×2016-12-31
2018-01-3123.64×2016-12-31
2018-02-2825×2016-12-31
2018-03-2923.88×2016-12-31
2018-04-3019.68×2016-12-31
2018-05-3119.87×2016-12-31
2018-06-2920.9×2016-12-31
2018-07-3122.18×2016-12-31
2018-08-3122.86×2016-12-31
2018-09-2823.44×2016-12-31
2018-10-3119.08×2016-12-31
2018-11-3020.19×2016-12-31
2018-12-3119.63×2016-12-31
2019-01-3118.64×2016-12-31
2019-02-2817.19×2018-12-31
2019-03-2915.87×2018-12-31
2019-04-3015.45×2018-12-31
2019-05-3115.1×2018-12-31
2019-06-2815.09×2018-12-31
2019-07-3114.78×2018-12-31
2019-08-3015.99×2018-12-31
2019-09-3016.87×2018-12-31
2019-10-3119.09×2018-12-31
2019-11-2916.45×2019-09-30
2019-12-3118.55×2019-09-30
2020-01-3118.19×2019-09-30
2020-02-2833.27×2019-12-31
2020-03-3131.4×2019-12-31
2020-04-3034.26×2019-12-31
2020-05-29141.35×2020-03-31
2020-06-30139.17×2020-03-31
2020-07-31138.84×2020-03-31
2020-08-31—2020-06-30
2020-09-30—2020-06-30
2020-10-30—2020-06-30
2020-11-30—2020-09-30
2020-12-31—2020-09-30
2021-01-29—2020-09-30
2021-02-26—2020-12-31
2021-03-31—2020-12-31
2021-04-30—2021-03-31
2021-05-28—2021-03-31
2021-06-30—2021-03-31
2021-07-30—2021-06-30
2021-08-31—2021-06-30
2021-09-30—2021-06-30
2021-10-29—2021-09-30
2021-11-30—2021-09-30
2021-12-31—2021-09-30
2022-01-31—2021-09-30
2022-02-2821.81×2021-12-31
2022-03-3123.19×2021-12-31
2022-04-2923.91×2021-12-31
2022-05-3123.96×2021-12-31
2022-06-3024.45×2021-12-31
2022-07-2923.43×2021-12-31
2022-08-3121.41×2021-12-31
2022-09-3022.58×2021-12-31
2022-10-3124.92×2022-09-30
2022-11-3025.83×2022-09-30
2022-12-3023.15×2022-09-30
2023-01-3123.37×2022-09-30
2023-02-2823.13×2022-12-31
2023-03-3123.25×2022-12-31
2023-04-2819.3×2023-03-31
2023-05-3118.62×2023-03-31
2023-06-3018.48×2023-03-31
2023-07-3116.42×2023-06-30
2023-08-3116.27×2023-06-30
2023-09-2915.32×2023-06-30
2023-10-3112.84×2023-09-30
2023-11-3012.3×2023-09-30
2023-12-2912.78×2023-09-30
2024-01-3112.17×2023-09-30
2024-02-2912.64×2023-09-30
2024-03-2813.51×2023-09-30
2024-04-30—2024-03-31
2024-05-31—2024-03-31
2024-06-28—2024-03-31
2024-07-31—2024-06-30
2024-08-30—2024-06-30
2024-09-30—2024-06-30
2024-10-31—2024-06-30
2024-11-29—2024-09-30
2024-12-31—2024-09-30
2025-01-31—2024-09-30
2025-02-28—2024-12-31
2025-03-31—2024-12-31
2025-04-30—2024-12-31
2025-05-30—2024-12-31
2025-06-30—2024-12-31
2025-07-31—2024-12-31
2025-08-29—2024-12-31
2025-09-30—2024-12-31
2025-10-3115.56×2025-09-30
2025-11-2816.61×2025-09-30
2025-12-3118.21×2025-09-30
2026-01-3018.59×2025-09-30
2026-02-2718.03×2025-12-31
2026-03-3117.53×2025-12-31
2026-04-3017.51×2025-12-31
2026-05-2916.09×2026-03-31
2026-06-3016.21×2026-03-31
2026-07-3114.41×2026-06-30
2026-08-3114.74×2026-06-30
2026-09-2513.87×2026-06-30
Mean 29.51×Median 22.62×39% below median

ROIC

% · Annual / TTM

—
Operating income is unavailable in the extracted statements for this period.
Bristol Myers Squibb Co ROIC. Reported fiscal history.
Fiscal period% · Annual / TTM
FY 2009 Q2—
FY 2009 Q3—
FY 2009 Q4—
FY 2010 Q1—
FY 2010 Q2—
FY 2010 Q3—
FY 2010 Q4—
FY 2011 Q1—
FY 2011 Q2—
FY 2011 Q3—
FY 2011 Q4—
FY 2012 Q1—
FY 2012 Q2—
FY 2012 Q3—
FY 2012 Q4—
FY 2013 Q1—
FY 2013 Q2—
FY 2013 Q3—
FY 2013 Q4—
FY 2014 Q1—
FY 2014 Q2—
FY 2014 Q3—
FY 2014 Q4—
FY 2015 Q1—
FY 2015 Q2—
FY 2015 Q3—
FY 2015 Q4—
FY 2016 Q1—
FY 2016 Q2—
FY 2016 Q3—
FY 2016 Q4—
FY 2017 Q1—
FY 2017 Q2—
FY 2017 Q3—
FY 2017 Q4—
FY 2018 Q1—
FY 2018 Q2—
FY 2018 Q3—
FY 2018 Q4—
FY 2019 Q1—
FY 2019 Q2—
FY 2019 Q3—
FY 2019 Q4—
FY 2020 Q1—
FY 2020 Q2—
FY 2020 Q3—
FY 2020 Q4—
FY 2021 Q1—
FY 2021 Q2—
FY 2021 Q3—
FY 2021 Q4—
FY 2022 Q1—
FY 2022 Q2—
FY 2022 Q3—
FY 2022 Q4—
FY 2023 Q1—
FY 2023 Q2—
FY 2023 Q3—
FY 2023 Q4—
FY 2024 Q1—
FY 2024 Q2—
FY 2024 Q3—
FY 2024 Q4—
FY 2025 Q1—
FY 2025 Q2—
FY 2025 Q3—
FY 2025 Q4—
FY 2026 Q1—
FY 2026 Q2—

Capital allocation

% of tracked cash uses

$2,903M
Bristol Myers Squibb Co capital allocation. Quarterly values. Missing values are unavailable.
PeriodCapexAcquisitionsBuybacksDividendsDebt repaymentsTracked uses
FY 2009 Q221.05% · $164MUnavailableUnavailable78.95% · $615MUnavailable100% · $779M
FY 2009 Q35.47% · $169M72.19% · $2,232MUnavailable20.25% · $626M2.1% · $65M100% · $3,092M
FY 2009 Q421.73% · $196M0% · $0MUnavailable69.4% · $626M8.87% · $80M100% · $902M
FY 2010 Q118.97% · $129MUnavailable0% · $0M81.03% · $551M0% · $0M100% · $680M
FY 2010 Q210.15% · $81MUnavailable20.68% · $165M69.17% · $552MUnavailable100% · $798M
FY 2010 Q310.76% · $89MUnavailable22.73% · $188M66.51% · $550MUnavailable100% · $827M
FY 2010 Q46.98% · $125MUnavailable12.45% · $223M30.65% · $549M49.92% · $894M100% · $1,791M
FY 2011 Q18.91% · $75MUnavailable17.58% · $148M67.1% · $565M6.41% · $54M100% · $842M
FY 2011 Q28.22% · $74MUnavailable26.33% · $237M62.78% · $565M2.67% · $24M100% · $900M
FY 2011 Q37.49% · $84MUnavailable42.25% · $474M50.27% · $564M0% · $0M100% · $1,122M
FY 2011 Q412.12% · $134M4.52% · $50M32.73% · $362M50.63% · $560M0% · $0M100% · $1,106M
FY 2012 Q13.38% · $123M68.42% · $2,491M9.31% · $339M15.9% · $579M2.99% · $109M100% · $3,641M
FY 2012 Q29.35% · $113M0% · $0M43.09% · $521M47.56% · $575M0% · $0M100% · $1,209M
FY 2012 Q31.56% · $137M57.28% · $5,039M11.95% · $1,051M6.49% · $571M22.72% · $1,999M100% · $8,797M
FY 2012 Q414.25% · $175M0% · $0M40.07% · $492M45.68% · $561M0% · $0M100% · $1,228M
FY 2013 Q111.59% · $115MUnavailable29.94% · $297M58.47% · $580MUnavailable100% · $992M
FY 2013 Q212.96% · $98MUnavailable10.98% · $83M76.06% · $575MUnavailable100% · $756M
FY 2013 Q39.18% · $124MUnavailable3.92% · $53M42.71% · $577M44.19% · $597M100% · $1,351M
FY 2013 Q425.74% · $200MUnavailable0% · $0M74.26% · $577M0% · $0M100% · $777M
FY 2014 Q18.31% · $118M1.48% · $21MUnavailable42.61% · $605M47.61% · $676M100% · $1,420M
FY 2014 Q212.22% · $110M21.33% · $192MUnavailable66.44% · $598M0% · $0M100% · $900M
FY 2014 Q315.2% · $107M0% · $0MUnavailable84.8% · $597M0% · $0M100% · $704M
FY 2014 Q424.03% · $191M0.75% · $6MUnavailable75.22% · $598M0% · $0M100% · $795M
FY 2015 Q117.92% · $136MUnavailableUnavailable82.08% · $623MUnavailable100% · $759M
FY 2015 Q221.05% · $165MUnavailableUnavailable78.95% · $619MUnavailable100% · $784M
FY 2015 Q326.35% · $234M4.17% · $37MUnavailable69.48% · $617M0% · $0M100% · $888M
FY 2015 Q425.4% · $285M19.52% · $219MUnavailable55.08% · $618M0% · $0M100% · $1,122M
FY 2016 Q121.57% · $242M0.71% · $8M20.59% · $231M57.13% · $641MUnavailable100% · $1,122M
FY 2016 Q222.6% · $261M22.42% · $259M0% · $0M54.98% · $635MUnavailable100% · $1,155M
FY 2016 Q333.4% · $341M4.31% · $44M0% · $0M62.29% · $636MUnavailable100% · $1,021M
FY 2016 Q435.2% · $371M4.55% · $48M0% · $0M60.25% · $635MUnavailable100% · $1,054M
FY 2017 Q19.52% · $291M3.66% · $112M65.4% · $2,000M21.42% · $655MUnavailable100% · $3,058M
FY 2017 Q222.59% · $248M18.85% · $207M0% · $0M58.56% · $643MUnavailable100% · $1,098M
FY 2017 Q311.78% · $262M15.87% · $353M9.89% · $220M28.76% · $640M33.71% · $750M100% · $2,225M
FY 2017 Q421.56% · $254M3.06% · $36M21.14% · $249M54.24% · $639M0% · $0M100% · $1,178M
FY 2018 Q117.13% · $239M24.09% · $336M11.97% · $167M46.81% · $653M0% · $0M100% · $1,395M
FY 2018 Q210.74% · $198M45.23% · $834M8.3% · $153M35.47% · $654M0.27% · $5M100% · $1,844M
FY 2018 Q324.3% · $224M4.88% · $45M0% · $0M70.82% · $653M0% · $0M100% · $922M
FY 2018 Q429.77% · $290M3.18% · $31M0% · $0M67.04% · $653M0% · $0M100% · $974M
FY 2019 Q19.54% · $204M0.7% · $15M0% · $0M31.29% · $669M58.47% · $1,250M100% · $2,138M
FY 2019 Q221.18% · $191M3.77% · $34M0% · $0M74.39% · $671M0.67% · $6M100% · $902M
FY 2019 Q316.24% · $190M0.77% · $9M25.64% · $300M57.35% · $671M0% · $0M100% · $1,170M
FY 2019 Q40.62% · $251M60.69% · $24,576M17.29% · $7,000M1.65% · $668M19.76% · $8,000M100% · $40,495M
FY 2020 Q114.21% · $186M1.91% · $25M6.19% · $81M77.69% · $1,017M0% · $0M100% · $1,309M
FY 2020 Q210.04% · $131M11.72% · $153M0% · $0M78.24% · $1,021M0% · $0M100% · $1,305M
FY 2020 Q35.25% · $153M8.34% · $243M0% · $0M34.89% · $1,016M51.51% · $1,500M100% · $2,912M
FY 2020 Q41.7% · $283M75.91% · $12,663M8.78% · $1,465M6.12% · $1,021M7.49% · $1,250M100% · $16,682M
FY 2021 Q12.27% · $173M0.46% · $35M23.32% · $1,775M14.55% · $1,108M59.4% · $4,522M100% · $7,613M
FY 2021 Q25.37% · $210M9.36% · $366M31.6% · $1,236M28.1% · $1,099M25.57% · $1,000M100% · $3,911M
FY 2021 Q37.84% · $270M30.71% · $1,057M15.25% · $525M31.67% · $1,090M14.53% · $500M100% · $3,442M
FY 2021 Q47.4% · $320M3.52% · $152M63.65% · $2,751M25.43% · $1,099M0% · $0M100% · $4,322M
FY 2022 Q12% · $253M3.49% · $442M39.53% · $5,000M9.37% · $1,185M45.61% · $5,769M100% · $12,649M
FY 2022 Q25.71% · $272M9.8% · $467M0% · $0M24.13% · $1,150M60.37% · $2,877M100% · $4,766M
FY 2022 Q33.03% · $247M40.02% · $3,261M8.6% · $701M14.16% · $1,154M34.18% · $2,785M100% · $8,148M
FY 2022 Q48.6% · $346M2.88% · $116M60.05% · $2,416M28.46% · $1,145M0% · $0M100% · $4,023M
FY 2023 Q18.08% · $278M2.27% · $78M7.26% · $250M34.75% · $1,196M47.65% · $1,640M100% · $3,442M
FY 2023 Q29.3% · $259M6.61% · $184M32.51% · $905M43% · $1,197M8.58% · $239M100% · $2,784M
FY 2023 Q35.84% · $342M5.56% · $326M68.27% · $4,000M20.33% · $1,191M0% · $0M100% · $5,859M
FY 2023 Q48.11% · $330M14.27% · $581M0% · $0M28.49% · $1,160M49.13% · $2,000M100% · $4,071M
FY 2024 Q11.32% · $284M93.06% · $20,053M0% · $0M5.62% · $1,212M0% · $0M100% · $21,549M
FY 2024 Q28.07% · $262M42.29% · $1,373M0% · $0M37.48% · $1,217M12.17% · $395M100% · $3,247M
FY 2024 Q37.42% · $324M7.97% · $348M0% · $0M27.85% · $1,216M56.76% · $2,478M100% · $4,366M
FY 2024 Q423.01% · $378M2.86% · $47M0% · $0M74.13% · $1,218M0% · $0M100% · $1,643M
FY 2025 Q116.29% · $260M4.89% · $78MUnavailable78.82% · $1,258M0% · $0M100% · $1,596M
FY 2025 Q214.15% · $361M11.17% · $285MUnavailable49.47% · $1,262M25.21% · $643M100% · $2,551M
FY 2025 Q38.68% · $320M50.84% · $1,874MUnavailable34.26% · $1,263M6.21% · $229M100% · $3,686M
FY 2025 Q42.76% · $370M12.73% · $1,707MUnavailable9.41% · $1,262M75.1% · $10,068M100% · $13,407M
FY 2026 Q115.81% · $347M2.96% · $65MUnavailable58.45% · $1,283M22.78% · $500M100% · $2,195M
FY 2026 Q210.51% · $305M3.13% · $91MUnavailable44.33% · $1,287M42.03% · $1,220M100% · $2,903M

Tracked cash uses · SBC excluded

Sources and calculations

Company filings · USD · Last checked 2026-10-18. Missing inputs remain unavailable. Your chart selection and layout are saved in this browser for Bristol Myers Squibb Co.

All charts share the selected dates. Quarterly/Yearly changes fiscal charts; valuation keeps completed daily closes on a published TTM basis. Later restatements can delay that basis. Historical mean, median and pricing labels use the selected range and do not estimate intrinsic fair value.

SBC deduction is an optional economic-cost scenario for FCF-based metrics. Missing SBC never becomes zero.

Revenue
Reported revenue from company filings.
Free cash flow
Operating cash flow − reported cash capital investment. PPE purchases are preferred; the productive-assets fallback also includes software and intangibles. Reflects the SBC option and can differ from issuer-defined FCF.
Net margin
Reported net income / revenue × 100.
P/E
Completed closing price × diluted shares / TTM earnings attributable to common shareholders.
ROIC
NOPAT / average invested capital × 100. NOPAT = operating income × (1 − effective tax rate). Invested capital = equity including noncontrolling interests + debt − cash and equivalents. Average uses period end and one year earlier.
Capital allocation
Reported cash uses as a percentage of tracked uses. Missing categories remain unavailable; SBC is noncash and excluded.
Reported revenue and sources